Wyndham H Wilson
Overview
Explore the profile of Wyndham H Wilson including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
209
Citations
15863
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Lakhotia R, Melani C, Dunleavy K, Pittaluga S, Desai S, Ahlman M, et al.
Leuk Lymphoma
. 2025 Feb;
:1-12.
PMID: 39899393
Immune cells within the lymphoma tumor microenvironment promote immune evasion and are rational therapeutic targets. Alemtuzumab targets CD52 expressed on malignant B-cells and infiltrating nonmalignant T-cells. We evaluated the safety...
2.
Ceribelli M, Tosto F, Zhang X, Melani C, Roschewski M, Beck E, et al.
Proc Natl Acad Sci U S A
. 2024 Nov;
121(49):e2413372121.
PMID: 39585996
Clinical trials in cancer are ideally built on a foundation of sound mechanistic rationale and well-validated drug activity in relevant disease models. The screening of approved and investigational drugs in...
3.
Melani C, Lakhotia R, Pittaluga S, Phelan J, Huang D, Wright G, et al.
N Engl J Med
. 2024 Jun;
390(23):2143-2155.
PMID: 38899693
Background: The identification of oncogenic mutations in diffuse large B-cell lymphoma (DLBCL) has led to the development of drugs that target essential survival pathways, but whether targeting multiple survival pathways...
4.
Choi J, Ceribelli M, Phelan J, Haupl B, Huang D, Wright G, et al.
Cancer Cell
. 2024 May;
42(5):833-849.e12.
PMID: 38701792
Glucocorticoids have been used for decades to treat lymphomas without an established mechanism of action. Using functional genomic, proteomic, and chemical screens, we discover that glucocorticoids inhibit oncogenic signaling by...
5.
Desai J, Zarakas M, Wishart A, Roschewski M, Aufiero M, Donko A, et al.
J Clin Invest
. 2024 May;
134(12).
PMID: 38696257
We describe a previously unappreciated role for Bruton's tyrosine kinase (BTK) in fungal immune surveillance against aspergillosis, an unforeseen complication of BTK inhibitors (BTKi) used for treating B cell lymphoid...
6.
Radtke A, Postovalova E, Varlamova A, Bagaev A, Sorokina M, Kudryashova O, et al.
Cancer Cell
. 2024 Mar;
42(3):444-463.e10.
PMID: 38428410
Follicular lymphoma (FL) is a generally incurable malignancy that evolves from developmentally blocked germinal center (GC) B cells. To promote survival and immune escape, tumor B cells undergo significant genetic...
7.
Lakhotia R, Dunleavy K, Abramson J, Link B, Powell B, Melani C, et al.
Blood Adv
. 2023 Jun;
7(18):5320-5324.
PMID: 37389844
No abstract available.
8.
Melani C, Dowdell K, Pittaluga S, Dunleavy K, Roschewski M, Song J, et al.
Lancet Haematol
. 2023 Apr;
10(5):e346-e358.
PMID: 37011643
Background: Lymphomatoid granulomatosis is a rare Epstein-Barr virus-associated B-cell lymphoproliferative disorder with a median overall survival of less than 2 years. In this study, we hypothesised that low-grade lymphomatoid granulomatosis...
9.
Torka P, Pederson L, Knopp M, Poon D, Zhang J, Kahl B, et al.
Cancer Med
. 2023 Feb;
12(7):8211-8217.
PMID: 36799072
Background: Quantitative methods of Fluorodeoxyglucose Positron Emission Tomography (FDG-PET) interpretation, including the percent change in FDG uptake from baseline (ΔSUV), are under investigation in lymphoma to overcome challenges associated with...
10.
Johnson P, Balasubramanian S, Hodkinson B, Shreeve S, Sun S, Srinivasan S, et al.
Blood Adv
. 2023 Jan;
7(10):2008-2017.
PMID: 36696540
Diffuse large B-cell lymphoma (DLBCL), with high coexpression of BCL2 and MYC proteins (DE lymphoma), is considered an adverse prognostic indicator associated mostly with non-germinal center B-cell-like (non-GCB) DLBCL. BCL2/MYC...